Overview

A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma

Status:
Recruiting

Trial end date:
2023-01-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

Karyopharm Therapeutics Inc

Treatments:

Bortezomib
Dexamethasone